Key result
COVID-19 pandemic linked to decreased invasive therapies and increased pharmacotherapy for ACS.
Why the study?
The COVID-19 pandemic has severely affected healthcare systems worldwide, and its impact on ACS clinical practice patterns was unclear.
How did the COVID-19 pandemic affect acute coronary syndrome clinical practice patterns among cardiologists in China?
Cross-Sectional (n=211)
Yes
How did the COVID-19 pandemic affect acute coronary syndrome clinical practice patterns among cardiologists in China?
p-value: p=<0.05
The COVID-19 pandemic significantly shifted ACS management in China from invasive therapies to pharmacotherapy.
Observed shift to pharmacotherapy in ACS during COVID-19 in China should not yet change practice; leaves open durability and outcome effects.
Background: The coronavirus disease 2019 (COVID-19) pandemic has severely affected healthcare systems around the world. This study aimed to investigate the perceptions of cardiologists regarding how the COVID-19 pandemic has affected the clinical practice patterns for acute coronary syndrome (ACS). Methods: A multicenter clinician survey was sent to 300 cardiologists working in 22 provinces in China. The survey collected demographic information and inquired about their perceptions of how the COVID-19 pandemic has affected ACS clinical practice patterns. Results: The survey was completed by 211 (70.3%) cardiologists, 82.5% of whom were employed in tertiary hospitals, and 52.1% reported more than 10 years of clinical cardiology practice. Most respondents observed a reduction in ACS inpatients and outpatients in their hospitals during the pandemic. Only 29.9% of the respondents had access to a dedicated catheter room for the treatment of COVID-19-positive ACS patients. Most respondents stated that the COVID-19 pandemic had varying degrees of effect on the treatment of acute ST-segment elevation myocardial infarction (STEMI), acute non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Compared with the assumed non-pandemic period, in the designed clinical questions, the selection of coronary interventional therapy for STEMI, NSTEMI, and unstable angina during the COVID-19 pandemic was significantly decreased (all p < 0.05), and the selection of pharmacotherapy was increased (all p < 0.05). The selection of fibrinolytic therapy for STEMI during the pandemic was higher than in the assumed non-pandemic period (p < 0.05). Conclusions: The COVID-19 pandemic has profoundly affected ACS clinical practice patterns. The use of invasive therapies significantly decreased during the pandemic period, whereas pharmacotherapy was more often prescribed by the cardiologists.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2022) conducted a cross-sectional in Acute Coronary Syndrome (ACS) clinical practice patterns (n=211). COVID-19 pandemic vs. Assumed non-pandemic period was evaluated on Selection of coronary interventional therapy vs pharmacotherapy for STEMI, NSTEMI, and unstable angina (p=<0.05). The COVID-19 pandemic significantly decreased the selection of invasive therapies for acute coronary syndrome and increased the use of pharmacotherapy compared to the assumed non-pandemic period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: